Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma

Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma is organized by i3 Health and will be held from Aug 10, 2023 - Aug 09, 2024.

STATEMENT OF NEED:
Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and the prognosis is very poor. In recent decades, the identification of genetic alterations in soft tissue sarcoma has led to the rise of targeted therapy, significantly expanding the therapeutic landscape. Remaining up to date on pathological characteristics and emerging data on novel therapies is crucial (Riskjell et al, 2023; NCI, 2023). In this Virtual Tumor Board, Shreyaskumar R. Patel, MD, Medical Director of the Sarcoma Center at the University of Texas MD Anderson Cancer Center; Kathleen Polson, NP, Nurse Practitioner at Dana-Farber Cancer Institute; and Brian Rubin, MD, PhD, Professor of Pathology at Cleveland Clinic Cancer Center, will present cases and explore multidisciplinary strategies to optimize treatment outcomes for patients with advanced soft tissue sarcoma. 

LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to

• Distinguish patient and tumor characteristics that can inform personalized therapeutic approaches in soft tissue sarcoma
• Evaluate emerging data on novel therapies for soft tissue sarcoma
• Appraise multidisciplinary strategies to optimize treatment outcomes of patients with advanced soft tissue sarcoma